In sorafenib, the predicted IC50 between the high-risk group and the low-risk group did not reach statistical significance ( p > 0.05) (Figure S2A), suggesting that the risk model has limited ability to distinguish the efficacy of sorafenib.
← all excerpts
Identification of a novel platelet-related prognostic model for hepatocellular carcinoma.
1
0.0500
0.0500